Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks: A noninferiority phase III trial (SAKK 96/12, REDUSE)
Jul 7, 2014
Background: Denosumab, a monoclonal antibody against RANK-Ligand has been shown to be superior to zoledronic acid in delaying time to a first on-study skeletal-related event (SRE) in patients with solid tumors, with no effects on disease progression...
Clinical Studies -
Jul 7, 2014 - Dec 31, 2026
Ongoing
Project leader: Fischer Stefanie
Members: Sakic Miranda, Quinter Janine
more
